Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 5, Pages 1918-1931Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI91406
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) KAKENHI [16H05337]
- Dainippon Sumitomo Pharma Co., Ltd.
- Grants-in-Aid for Scientific Research [15K09478, 16H05337, 17H05649, 15H01513] Funding Source: KAKEN
Ask authors/readers for more resources
The eleven-nineteen leukemia (ENL) protein family, composed of ENL and AF9, is a common component of 3 transcriptional modulators: AF4-ENL-P-TEFb complex (AEP), DOT1L-AF10-ENL complex (referred to as the DOT1L complex) and polycomb-repressive complex 1 (PRC1). Each complex associates with chromatin via distinct mechanisms, conferring different transcriptional properties including activation, maintenance, and repression. The mixed-lineage leukemia (MLL) gene often fuses with ENL and AF10 family genes in leukemia. However, the functional interrelationship among those 3 complexes in leukemic transformation remains largely elusive. Here, we have shown that MLL-ENL and MLL-AF10 constitutively activate transcription by aberrantly inducing both AEP-dependent transcriptional activation and DOT1L-dependent transcriptional maintenance, mostly in the absence of PRC1, to fully transform hematopoietic progenitors. These results reveal a cooperative transcriptional activation mechanism of AEP and DOT1L and suggest a molecular rationale for the simultaneous inhibition of the MLL fusion-AF4 complex and DOT1L for more effective treatment of MLL-rearranged leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available